Patient advocates and progressives had hoped the administration would use its executive powers to enable production of generic versions of Xtandi, a prostate cancer drug developed with federal funding at The drug’s manufacturer charges up to $190,000 a year…
Read MoreArthur Allen USE OUR CONTENTThis story can be republished for free No Byline Policy Editorial Guidelines Corrections Policy Source
Read MoreCNN — When a pharmaceutical plant in Shanghai that made contrast material for radiological scans shut down last year, half the United States’ supply of the radioactive substance immediately became Health care providers had to make difficult choices about…
Read MoreMedical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in the [+] background in this illustration photo taken in Krakow, Poland on November 10, (Photo by Jakub Porzycki/NurPhoto via Getty Images)NurPhoto…
Read MoreAccording to experts, this will help them expand their shares in the domestic market which remains dominated by imported drugs and extend their international Vietnam’s pharmaceutical market has significant The Health Ministry estimated the market at (RM31bil)…
Read More$79 million for the Naloxone Distribution Project to meet increased demand and provide more Naloxone to communities than ever before; $10 million for grants for education, testing, recovery, and support services; $4 million to make fentanyl test strips more widely available;…
Read MoreThe president announced a national biotechnology and biomanufacturing strategy in September to strengthen supply chains, create American jobs and ward off competition, particularly from has allocated $2bn in initial funding to support the strategy and asked stakeholders in the…
Read MoreCalifornia Gavin Newsom on Saturday announced a partnership with drugmaker Civica Rx, to offer insulin at a dramatically lower cost, during a visit to a Kaiser Permanente warehouse storing thousands of insulin drug doses in Downey, on
Read MoreThe maker of slimming jab Wegovy was facing crises on multiple fronts this weekend, with the UK medicines regulator announcing a review of its operations at the same time as an investigation is under way into the approval of its…
Read More“Going forward, ICRA expects revenues for its sample set to increase by 6-8 percent in FY2024 against 3-4 percent growth in FY2023,” ICRA Assistant Vice President & Sector Head – Corporate Ratings Mythri Macherla said in a factors such…
Read More
